Mylan Inc


  • Hospira filed a lawsuit in U.S. District Court in Maryland on Tuesday asking for a temporary restraining order against the FDA, saying the agency's decision to allow generic Precedex went against its own rules.

  • WASHINGTON, Aug 7- An influential U.S. senator is encouraging the Internal Revenue Service to stamp out deals that allow companies to relocate their headquarters overseas in search of lower tax rates.

  • *Expects key drug launches in fourth quarter despite FDA delay. Aug 7- Political opposition to tax-inversion deals will not stop Mylan Inc's purchase of some non-U.S. businesses from Abbott Laboratories, Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.

  • *Cuts top end of FY earnings forecast to $3.45/ shr from $3.60/ shr. Aug 7- Mylan Inc shaved the top end of its full-year revenue and earnings forecasts, citing delays in approval from the U.S. Food and Drug Administration for key generic drugs that it plans to launch this year.

  • Mylan narrows full-year revenue, profit forecast Thursday, 7 Aug 2014 | 6:48 AM ET

    Aug 7- Generic drug maker Mylan Inc narrowed its full-year revenue and earnings forecast, citing delays in U.S. Food and Drug Administration approval of key products. The company narrowed its revenue forecast range to $7.8 billion- $8 billion from $7.8 billion- $8.2 billion.

  • Early movers: SBUX, V, AMZN, WMT, Z, XOM & more Friday, 25 Jul 2014 | 7:44 AM ET

    Some of the names on the move ahead of the open.

  • Did Congress prescribe Obamacare a 'poison pill?' Thursday, 24 Jul 2014 | 2:50 PM ET
    Felue Chang who is newly insured through the Affordable Care Act receives a checkup from Dr. Peria Del Pino-White at the South Broward Community Health Services clinic on April 15, 2014 in Hollywood, Florida.

    Surely Congress didn't mean to include a "poison pill" for the Affordable Care Act when it passed it, says law professor Tim Jost.

  • Who gets the last word on Obamacare? Wednesday, 23 Jul 2014 | 10:23 AM ET

    After a split ruling on Obamacare from the courts, who gets the last word? Law professor Dan Eaton weighs in.

  • US companies sit at a crossroads on tax inversions Saturday, 19 Jul 2014 | 8:54 AM ET
    A Walgreens store on June 19, 2012 in San Francisco, California.

    U.S. Treasury Secretary Jack Lew highlighted the decision American companies face—stay domestic and pay taxes or go abroad for savings.

  • Is patriotism a virtue in business? Friday, 18 Jul 2014 | 7:00 AM ET

    Do US firms have a duty to sacrifice their own interests for the broader good of the country?, asks law professor Dan Eaton.

  • July 16- Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday as demand for its recently-recalled infant formulas began to recover and profit margins improved for other business segments.

  • Sanofi mulls selling mature drug portfolio: Report Wednesday, 16 Jul 2014 | 8:39 AM ET

    Sanofi talked with Abbott Laboratories, Mylan and private equity firms over selling a portfolio of mature drugs, according to a document.

  • Jack Lew pushes for crackdown on tax inversions Wednesday, 16 Jul 2014 | 6:19 AM ET
    Jack Lew, U.S. Treasury Secretary.

    Treasury Secretary Jack Lew has urged Congress to crack down on merger deals in which companies seek to relocate overseas to cut US taxes.

  • How US drug firms plan to evade taxes Tuesday, 15 Jul 2014 | 5:35 AM ET

    Increasingly, drug makers and medical device companies have found a way to self-medicate when it comes to taxes and regulation.

  • *Citigroup to pay $7 bln to settle U.S. mortgage probe. NEW YORK, July 14- U.S. stocks ended higher on Monday, with the Dow Jones industrial average hitting an intraday record, lifted by Citigroup's better-than-expected earnings and more deals in the healthcare space. Citigroup Inc shares jumped 3 percent to $48.42 and gave the S&P 500 one of its biggest boosts.

  • Stocks end higher on M&A; Dow sets intraday record Monday, 14 Jul 2014 | 4:50 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks climbed on Monday, with the S&P 500 bouncing back from weekly losses, after Citigroup's earnings beat estimates.

  • *Citigroup to pay $7 bln to settle U.S. mortgage probe. NEW YORK, July 14- U.S. stocks rose on Monday with the Dow Jones industrial average hitting a new intraday high, lifted by better than expected earnings from Citigroup and more deals in the healthcare space.

  • July 14- Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.

  • *Citigroup up after earnings, settlement. NEW YORK, July 14- U.S. stocks rose on Monday, sparked by the latest flurry of merger activity and earnings from Citigroup, putting the S&P 500 on pace to climb for a second straight session.

  • Big shale deal may be easy money or strong market Monday, 14 Jul 2014 | 10:03 AM ET
    Traders on the floor of the New York Stock Exchange.

    Big mergers are afoot. But is a major shale oil deal a sign of a strong market?